Search

Researchers at Peking Union Medical College Hospital conducted a bibliometric analysis of research on medullary thyroid carcinoma (MTC) from 2000 to 2022. The study found a gradual increase in MTC-related literature over the past two decades, with the United States leading in publications. Key research areas include treatment, diagnosis, inhibitors, and exploring the pathogenesis of MTC. This information provides valuable insights into the current state and future trends in MTC research. [Extracted from the article]

Researchers from Ohio State University conducted a study on Medullary Thyroid Cancer (MTC) and identified CAPN1 as a key regulator of NF1 and RET fueled growth in MTC cells. The study found that CAPN1 inhibitors reduced MTC cell growth and synergized with existing therapies like vandetanib and selpercatinib. The research suggests that combinatorial therapies involving CAPN1 inhibitors and existing treatments show maximal efficacy in MTC cells. [Extracted from the article]

A study conducted at the University of Catania in Italy focused on Medullary Thyroid Cancer (MTC) in pediatric/adolescent carriers of the RET mutation. The research aimed to evaluate the genotype/phenotype correlation and outcomes in 23 patients under 19 years old who underwent thyroidectomy. The study found that genetic counseling and RET screening are crucial for first-degree relatives of patients with Multiple Endocrine Neoplasia type 2 syndrome (MEN2) to prevent the onset of MTC. Surgery for prophylactic purposes is recommended to reduce the risk of persistent or recurrent disease in pediatric/adolescent patients. [Extracted from the article]

Researchers at Hacettepe University School of Medicine have developed a new method, lymph node ACTH washout, to identify the source of ACTH production in a case of metastatic medullary thyroid carcinoma. This method was used on a 23-year-old male with Cushing's syndrome resulting from medullary thyroid cancer, leading to a diagnosis and subsequent treatment. The study highlights the potential effectiveness of lymph node ACTH washout as a diagnostic tool in cases of ACTH-dependent Cushing syndrome. [Extracted from the article]

The article discusses a case study from Rutgers University on metastatic medullary thyroid carcinoma presenting as an incidental posterior mediastinal mass. The research emphasizes the importance of testing for calcitonin in masses with neuroendocrine features to enable earlier detection of MTC and improve prognosis. This study highlights the significance of thorough testing for accurate diagnosis and treatment of rare neuroendocrine tumors like MTC. [Extracted from the article]

A recent study on medullary thyroid cancer conducted at the Affiliated Hospital of Nanjing University of Chinese Medicine in China highlights the challenges posed by this rare but aggressive form of thyroid malignancy. The research focuses on the molecular genetics of medullary thyroid cancer, particularly the role of the RET gene and the RAS gene family, offering insights into potential therapeutic targets and novel biomarkers. The study emphasizes the importance of precision therapies and the need for further research in this field to improve clinical practice and patient outcomes. [Extracted from the article]

A recent study conducted at the Memorial Sloan-Kettering Cancer Center has found that the protein SEZ6 is highly expressed in medullary thyroid carcinoma (MTC), a type of thyroid cancer. SEZ6 has also been found in small cell lung carcinoma (SCLC) and is being targeted by a novel antibody drug conjugate called ABBV-011, which is currently in clinical trials for treating SCLC and neuroendocrine neoplasms, including MTC. The study suggests that SEZ6 could serve as a biomarker for MTC and that SEZ6-targeted therapy shows promise as a targeted treatment for MTC, even in cases without specific genetic mutations. [Extracted from the article]

A recent report from SRM Medical College Hospital and Research Centre in Tamil Nadu, India, discusses a case of medullary thyroid cancer. The patient, a 64-year-old male with uncontrolled type 2 diabetes mellitus and peripheral vascular disease, presented with a swelling on the right side of his neck. The swelling had slowly progressed over the past five years and was accompanied by palpable lymph nodes. Blood investigations revealed a reduced hemoglobin level, but thyroid function tests were normal. This case highlights the importance of considering thyroid carcinoma in patients with palpable lymph nodes. [Extracted from the article]

Recent findings from the University of Rochester provide new insights into medullary thyroid cancer (MTC). MTC is a rare primary neuroendocrine thyroid carcinoma that is distinct from other thyroid or neuroendocrine cancers. Most cases of MTC are sporadic, but it exhibits a high degree of heritability. The primary oncogenic drivers of MTC are RET mutations, and advances in molecular profiling have revealed druggable alterations. Surgery at an early stage is the only chance for a cure, but many patients present with or develop metastases. Biomarkers such as C-cell-specific calcitonin trajectory and structural doubling times are critical for prognosis and treatment decisions. Recent advances in active surveillance, regionally directed therapies, and systemic therapy with multi-kinase and RET-specific inhibitors have significantly improved outcomes for patients with MTC. [Extracted from the article]

The article presents new findings from the University of Medicine and Pharmacy "Victor Babes" Timisoara on medullary thyroid carcinoma (MTC) in patients with Graves' disease. Topics discussed include the increased incidence of thyroid malignancies in Graves' disease patients, the case series of three women with MTC, and the recommendation for integrating calcitonin testing into standard diagnostic protocols.

A clinical trial, NCT06530316, is currently underway in China to evaluate the effectiveness and safety of RET inhibitors as neoadjuvant therapy for locally advanced RET-altered thyroid cancer. The trial involves administering RET inhibitors to patients in a real-world setting, followed by surgical treatment for those eligible. The study aims to assess various outcomes, including resection rate, objective response rate, disease control rate, time to objective response, progression-free survival, overall survival, and adverse events. The document provides information about an FDA-regulated device product without disclosing the collaborators or investigators. The keywords associated with this article cover topics such as pharmaceuticals, surgery, genetics, clinical research, thyroid neoplasms, drugs and therapies, health and medicine, neoadjuvant therapy, combined modality therapy, clinical trials and studies, medullary thyroid carcinoma, and oncology - medullary thyroid cancer. [Extracted from the article]

A recent study conducted at Tianjin Medical University Cancer Institute and Hospital in China investigated the expression and prognostic value of Aurora kinase A (AURKA) and tumor-infiltrating lymphocytes (TILs) in medullary thyroid carcinoma (MTC). The researchers collected surgical specimens and clinical data from 137 MTC patients and found that high expression of AURKA combined with low numbers of TILs was an independent prognostic factor for biochemical recurrence and recurrence-free survival. The combination of AURKA and TILs improved the prognostic value for MTC recurrence. The study concluded that the combination of AURKA and TILs could serve as a novel independent prognostic marker for MTC, accurately predicting incurable disease recurrence. [Extracted from the article]

A new report from Milan, Italy provides fresh data on medullary thyroid cancer (MTC). MTC accounts for only 3% of all thyroid carcinomas, with 75% being sporadic MTC (sMTC) and 25% being hereditary MTC (hMTC) in the context of multiple endocrine neoplasia type 2 (MEN2). Early diagnosis is possible through the determination of the tumor marker calcitonin (Ctn) and the detection of the mutation in the proto-oncogene RET in MEN2 families. Treatment options include surgery and tyrosine kinase inhibitors, depending on the stage of the cancer. The research emphasizes the importance of follow-up care and monitoring for tumor progression. [Extracted from the article]

A recent study conducted by researchers at Tianjin Medical University Cancer Institute and Hospital focused on medullary thyroid carcinoma (MTC), a rare malignant tumor. The study aimed to identify the time kinetics and risk factors associated with calcitonin normalization (CN) and biochemical persistence/recurrence (BP) in MTC patients. The study found that achieving CN within one week or one month after surgery was associated with better outcomes, while failure to achieve CN led to biochemical persistence/recurrence and structural recurrence. The study also identified certain predictors of CN and BP, such as lymph node ratio (LNR) and gender. The findings suggest that early changes in calcitonin levels can provide real-time prognostic information for MTC patients. [Extracted from the article]

Researchers from Binzhou Medical University in China have conducted a retrospective study on medullary thyroid carcinoma (MTC), a rare form of thyroid cancer. The study aimed to analyze the relationship between calcitonin (Ctn) levels at different time points in MTC patients and evaluate its predictive effect on recurrence. The study included 212 patients with a median follow-up time of 59.5 months. The findings showed that normalization of postoperative serum Ctn at the first month (NPS) was a better predictor of long-term biochemical cure for MTC than preoperative Ctn levels. Non-biochemical cure, larger tumor size, and multifocality were identified as unfavorable independent predictors of structural recurrence and disease-free survival. The study also found no difference in prognosis between different surgeries for sporadic MTC confined to the thyroid lobe. [Extracted from the article]

A recent report from the University of Padua in Italy discusses the role of procalcitonin (ProCt) in the follow-up of medullary thyroid cancer (MTC). The study found that ProCt and calcitonin (Ct) values were highly correlated, and ProCt may be useful as an adjunct to Ct in determining the presence or absence of structural disease in MTC patients. The research suggests that ProCt has a high negative predictive value (NPV) for detecting structural disease. Further research is needed to explore the potential of ProCt in MTC follow-up. [Extracted from the article]

A recent study conducted by researchers at Baylor College of Medicine in Houston, Texas, aimed to broaden the understanding of medullary thyroid cancer (MTC) in pediatric patients. The study analyzed the clinical presentations and long-term outcomes of 144 patients diagnosed with MTC between 1961 and 2019. The findings revealed that pediatric patients with sporadic MTC (sMTC) had older age at diagnosis, larger tumors, higher initial stage grouping, and more structural disease and distant metastases compared to those with hereditary MTC (hMTC). However, these differences disappeared when comparing patients diagnosed clinically, regardless of family history. The study also highlighted the importance of somatic molecular testing in sMTC patients who may benefit from systemic therapy. [Extracted from the article]

Researchers from Jagiellonian University College of Medicine in Krakow, Poland have published a case study on a 45-year-old male with ectopic ACTH-dependent Cushing's syndrome induced by medullary thyroid carcinoma (MTC). MTC is a rare neoplasm originating from thyroid parafollicular cells and is characterized by calcitonin production. In this case, the MTC released adrenocorticotropic hormone (ACTH), accounting for about 2% of ectopic Cushing's syndrome cases. The patient presented with weakness and a history of recent diabetes and hypertension. This research provides valuable insights into the relationship between MTC and Cushing's syndrome. [Extracted from the article]

A recent report from the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) discusses the treatment of medullary thyroid cancer (MTC). The study aimed to determine the prevalence of occult contralateral disease (lesions not seen on preoperative ultrasonography) in patients with MTC, in order to justify total thyroidectomy. The research found that among patients with sporadic MTC, there was a low prevalence of contralateral disease, suggesting that a staged approach involving initial thyroid lobectomy could be considered. The study recommends further research to evaluate lobectomy as a potential cure for patients with unilateral disease. [Extracted from the article]

Researchers from Zhejiang University School of Medicine in Hangzhou, China, have developed a nomogram model to predict the overall survival (OS) of patients with medullary thyroid carcinoma (MTC). The model was established using data from the Surveillance, Epidemiology, and End Results (SEER) database and validated using an external validation group. The model takes into account factors such as age, tumor size, N stage, and M stage to predict the OS of MTC patients. The study concludes that the nomogram model shows reliable predictive ability. [Extracted from the article]

A recent report from Tohoku University in Miyagi, Japan discusses a rare case of tumor-to-tumor metastasis in a patient with multiple endocrine neoplasia type 2B. The patient, a 36-year-old woman, had a history of medullary thyroid carcinoma and bilateral adrenalectomy for pheochromocytomas. The report describes the diagnosis and surgical resection of a retroperitoneal tumor and a liver tumor, which were found to be a paraganglioma recurrence and a metastasis of the medullary thyroid carcinoma, respectively. This is the first reported case of tumor-to-tumor metastasis of medullary thyroid carcinoma to paraganglioma in a patient with multiple endocrine neoplasia type 2B. [Extracted from the article]

A recent report from Martin Luther-University Halle-Wittenberg discusses the progress made in understanding multiple endocrine neoplasia type 2 (MEN2) and its implications for medullary thyroid cancer. The research highlights the importance of early identification and monitoring of carriers of the RET mutation, as well as the integration of molecular and biomarker results in determining the appropriate treatment approach. The study suggests that a risk-based approach, based on patient age, RET mutation, and biomarker levels, can guide decisions regarding surgery and preventive healthcare. The findings emphasize the need for broader testing and education in order to transition from symptom-based to preventive healthcare. [Extracted from the article]

Keywords: New York City; State:New York; United States; North and Central America; Cancer; Carcinomas; Endocrinology; Health and Medicine; Medullary Thyroid Cancer; Oncology; Software; Thyroid Cancer EN New York City State:New York United States North and Central America Cancer Carcinomas Endocrinology Health and Medicine Medullary Thyroid Cancer Oncology Software Thyroid Cancer 1772 1772 1 11/06/23 20231107 NES 231107 2023 NOV 6 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Week -- Researchers detail new data in Oncology - Medullary Thyroid Cancer. Medullary Thyroid Cancer, Oncology, Software, Thyroid Cancer, New York City, State:New York, United States, North and Central America, Cancer, Carcinomas, Endocrinology, Health and Medicine We herein validate a machine learningbased deep-learning platform and an image analysis software with internal thresholding to generate accurate automatic Ki67 proliferation indices in medullary thyroid carcinoma. [Extracted from the article]

Cancer, Health and Medicine, Medullary Thyroid Cancer, Oncology, Thyroid Cancer, Thyroid Neoplasms Keywords: Cancer; Health and Medicine; Medullary Thyroid Cancer; Oncology; Thyroid Cancer; Thyroid Neoplasms EN Cancer Health and Medicine Medullary Thyroid Cancer Oncology Thyroid Cancer Thyroid Neoplasms 939 939 1 10/24/23 20231024 NES 231024 2023 OCT 24 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Week -- New research on medullary thyroid cancer is the subject of a new report. [Extracted from the article]

Keywords: Cancer; Health and Medicine; Medullary Thyroid Cancer; Oncology; Thyroid Cancer; Thyroid Neoplasms EN Cancer Health and Medicine Medullary Thyroid Cancer Oncology Thyroid Cancer Thyroid Neoplasms 762 762 1 09/25/23 20230926 NES 230926 2023 SEP 26 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Week -- Current study results on medullary thyroid cancer have been published. Cancer, Health and Medicine, Medullary Thyroid Cancer, Oncology, Thyroid Cancer, Thyroid Neoplasms. [Extracted from the article]

Cancer, Carcinomas, Drugs and Therapies, Endocrinology, Enzymes and Coenzymes, Health and Medicine, Kinase, Medullary Thyroid Cancer, Oncology, Personalized Medicine, Personalized Therapy, Proteins, Proteomics, Thyroid Cancer, Tyrosine Kinase Keywords: Cancer; Carcinomas; Drugs and Therapies; Endocrinology; Enzymes and Coenzymes; Health and Medicine; Kinase; Medullary Thyroid Cancer; Oncology; Personalized Medicine; Personalized Therapy; Proteins; Proteomics; Thyroid Cancer; Tyrosine Kinase EN Cancer Carcinomas Drugs and Therapies Endocrinology Enzymes and Coenzymes Health and Medicine Kinase Medullary Thyroid Cancer Oncology Personalized Medicine Personalized Therapy Proteins Proteomics Thyroid Cancer Tyrosine Kinase 940 940 1 07/31/23 20230801 NES 230801 2023 JUL 31 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Week -- Data detailed on personalized medicine have been presented. [Extracted from the article]

Keywords: Biomarkers; Calcitonin; Cancer; Cell Line; Cell Surface Receptors; Diagnostics and Screening; G-Protein-Coupled Receptors; Genetics; Health and Medicine; Hormones; Intracellular Signaling Peptides and Proteins; Medullary Thyroid Cancer; Membrane Proteins; Nerve Tissue Proteins; Neuropeptides; Odorant Receptors; Olfactory Marker Proteins; Oncology; Peptide Hormones; Peptide Proteins; Proteins; Thyroid Cancer; Thyroid Neoplasms EN Biomarkers Calcitonin Cancer Cell Line Cell Surface Receptors Diagnostics and Screening G-Protein-Coupled Receptors Genetics Health and Medicine Hormones Intracellular Signaling Peptides and Proteins Medullary Thyroid Cancer Membrane Proteins Nerve Tissue Proteins Neuropeptides Odorant Receptors Olfactory Marker Proteins Oncology Peptide Hormones Peptide Proteins Proteins Thyroid Cancer Thyroid Neoplasms 816 816 1 07/10/23 20230710 NES 230710 2023 JUL 11 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Week -- Current study results on medullary thyroid cancer have been published. This study evaluates the odorant receptor signals from parafollicular C-cells, specifically, the presence of olfactory marker protein, and further assesses the ability of the protein in localizing and treating medullary thyroid cancer. [Extracted from the article]

Keywords for this news article include: New Haven, Connecticut, United States, North and Central America, Cancer, Carcinomas, Endocrinology, Health and Medicine, Medullary Thyroid Cancer, Oncology, Thyroid Cancer, Yale University School of Medicine. Keywords: New Haven; State:Connecticut; United States; North and Central America; Cancer; Carcinomas; Endocrinology; Health and Medicine; Medullary Thyroid Cancer; Oncology; Thyroid Cancer EN New Haven State:Connecticut United States North and Central America Cancer Carcinomas Endocrinology Health and Medicine Medullary Thyroid Cancer Oncology Thyroid Cancer 375 375 1 06/05/23 20230606 NES 230606 2023 JUN 5 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Week -- Current study results on Oncology - Medullary Thyroid Cancer have been published. [Extracted from the article]

Calcitonin, Cancer, Carcinomas, Diagnostics and Screening, Endocrinology, Health and Medicine, Hormones, Medullary Thyroid Carcinoma, Medullary Thyroid Cancer, Neuropeptides, Oncology, Peptide Hormones, Peptide Proteins, Proteins, Thyroid Cancer Keywords: Calcitonin; Cancer; Carcinomas; Diagnostics and Screening; Endocrinology; Health and Medicine; Hormones; Medullary Thyroid Cancer; Medullary Thyroid Carcinoma; Neuropeptides; Oncology; Peptide Hormones; Peptide Proteins; Proteins; Thyroid Cancer EN Calcitonin Cancer Carcinomas Diagnostics and Screening Endocrinology Health and Medicine Hormones Medullary Thyroid Cancer Medullary Thyroid Carcinoma Neuropeptides Oncology Peptide Hormones Peptide Proteins Proteins Thyroid Cancer 994 994 1 06/05/23 20230606 NES 230606 2023 JUN 5 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Week -- Data detailed on medullary thyroid cancer have been presented. [Extracted from the article]

Keywords for this news article include: Memorial Sloan-Kettering Cancer Center, New York City, New York, United States, North and Central America, Oncology, Calcitonin, Neuropeptides, Peptide Hormones, Peptide Proteins, Thyroid Neoplasms, Health and Medicine, Medullary Thyroid Cancer. Calcitonin, Cancer, Health and Medicine, Hormones, Neuropeptides, Oncology, Peptide Hormones, Peptide Proteins, Proteins, Thyroid Cancer, Thyroid Neoplasms, Medullary Thyroid Cancer Keywords: Calcitonin; Cancer; Health and Medicine; Hormones; Medullary Thyroid Cancer; Neuropeptides; Oncology; Peptide Hormones; Peptide Proteins; Proteins; Thyroid Cancer; Thyroid Neoplasms EN Calcitonin Cancer Health and Medicine Hormones Medullary Thyroid Cancer Neuropeptides Oncology Peptide Hormones Peptide Proteins Proteins Thyroid Cancer Thyroid Neoplasms 686 686 1 05/22/23 20230523 NES 230523 2023 MAY 23 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Week -- Current study results on medullary thyroid cancer have been published. [Extracted from the article]

Keywords: Cancer; Carcinomas; Endocrinology; Health and Medicine; Medullary Thyroid Cancer; Oncology; Thyroid Cancer EN Cancer Carcinomas Endocrinology Health and Medicine Medullary Thyroid Cancer Oncology Thyroid Cancer 562 562 1 05/02/23 20230502 NES 230502 2023 MAY 1 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Week -- Fresh data on medullary thyroid cancer are presented in a new report. Cancer, Carcinomas, Endocrinology, Health and Medicine, Medullary Thyroid Cancer, Oncology, Thyroid Cancer. [Extracted from the article]

Keywords: Calcitonin; Cancer; Carcinomas; Endocrine Gland Neoplasms; Endocrinology; Health and Medicine; Hormones; Medullary Thyroid Cancer; Neuropeptides; Oncology; Peptide Hormones; Peptide Proteins; Proteins; Thyroid Cancer; Thyroid Diseases and Conditions; Thyroid Neoplasms; Thyroid Nodules EN Calcitonin Cancer Carcinomas Endocrine Gland Neoplasms Endocrinology Health and Medicine Hormones Medullary Thyroid Cancer Neuropeptides Oncology Peptide Hormones Peptide Proteins Proteins Thyroid Cancer Thyroid Diseases and Conditions Thyroid Neoplasms Thyroid Nodules 904 904 1 05/02/23 20230502 NES 230502 2023 MAY 1 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Week -- Researchers detail new data in medullary thyroid cancer. Calcitonin, Cancer, Carcinomas, Endocrine Gland Neoplasms, Endocrinology, Health and Medicine, Hormones, Medullary Thyroid Cancer, Neuropeptides, Oncology, Peptide Hormones, Peptide Proteins, Proteins, Thyroid Cancer, Thyroid Diseases and Conditions, Thyroid Neoplasms, Thyroid Nodules. [Extracted from the article]

Keywords: Biochemicals; Biochemistry; Cancer; Carcinomas; Chemicals; Endocrinology; Health and Medicine; Medullary Thyroid Cancer; Oncology; Surgery; Thyroid Cancer EN Biochemicals Biochemistry Cancer Carcinomas Chemicals Endocrinology Health and Medicine Medullary Thyroid Cancer Oncology Surgery Thyroid Cancer 2023 FEB 20 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Week -- Current study results on medullary thyroid cancer have been published. Biochemicals, Biochemistry, Cancer, Carcinomas, Chemicals, Endocrinology, Health and Medicine, Oncology, Surgery, Thyroid Cancer, Medullary Thyroid Cancer. [Extracted from the article]